<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">Brain ischemia</z:e> provoked by <z:hpo ids='HP_0001297'>stroke</z:hpo> or traumatic brain injury induces a massive increase in neurotransmitter release, in particular of the excitotoxin <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="6" ids="14321,29987">Glutamate</z:chebi> triggers a cascade of events finally leading to widespread neuronal cell damage and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The aminomethylchroman derivative BAY x 3702 is a novel neuroprotectant which shows pronounced beneficial effects in various animal models of ischemic brain injury </plain></SENT>
<SENT sid="3" pm="."><plain>As shown previously BAY x 3702 binds to <z:chebi fb="0" ids="28790">5-HT</z:chebi>(1A) receptors of different species in subnanomolar range and is characterized as a full receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>In this study we investigated the influence of BAY x 3702 on <z:chebi fb="120" ids="26216">potassium</z:chebi>-evoked <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release in vitro and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>In rat hippocampal slices BAY x 3702 inhibited evoked <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release in a dose-dependent manner (IC(50)=1 microM) </plain></SENT>
<SENT sid="6" pm="."><plain>This effect was blocked by the selective <z:chebi fb="0" ids="28790">5-HT</z:chebi>(1A) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> WAY 100635, indicating that BAY x 3702 specifically acts via <z:chebi fb="0" ids="28790">5-HT</z:chebi>(1A) receptors </plain></SENT>
<SENT sid="7" pm="."><plain>In vivo, release of endogenous <z:chebi fb="0" ids="29995">aspartate</z:chebi> and <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> was measured in the cortex of rats by microdialysis before and after <z:hpo ids='HP_0003674'>onset</z:hpo> of permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Single dose administration of BAY x 3702 (1 microg/kg or 10 microg/kg i.v.) immediately after occlusion reduced the increase and total release of extracellular <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> by about 50% compared to non-treated animals, whereas the extracellular <z:chebi fb="0" ids="29995">aspartate</z:chebi> levels were not significantly affected </plain></SENT>
<SENT sid="9" pm="."><plain>Inhibition of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release may therefore contribute to the pronounced neuroprotective efficacy of BAY x 3702 in various animal models of ischemic brain damage </plain></SENT>
</text></document>